HEALWELL AI's DARWEN™ platform demonstrated superior clinical summarization accuracy compared to OpenAI's GPT, DeepSeek, and Llama, with improvements of up to 43% on key evaluation metrics. It also showed nearly 50% higher treatment-plan accuracy than a top general AI model and helped identify over 4,100 heart failure patients not receiving proper therapy, leading to a 70% improvement in treatment optimization within six months. These results, presented at multiple 2026 scientific forums, highlight DARWEN™'s ability to deliver clinically relevant AI solutions that improve patient outcomes and support proactive care. HEALWELL is advancing from scientific validation to commercial deployment across health systems and pharmaceutical collaborations.
HEALWELL AI's DARWEN™ platform is the subject, here is Pluang's health sector snapshot as of Sep 15, 2026 16:41 WIB: Out of 91 priced US health stocks, 35 rose and 48 fell. Notable prices include Alcon AG (ALC) at USD 66.90 with a -1.24% change, Amylx Pharmaceuticals Inc (AMLX) at USD 33.23 with a -1.22% change, and Recursion Pharmaceuticals Inc (RXRX) at USD 3.37 with a -1.17% change.
Graphene Manufacturing Group Ltd. announced that CEO Craig Nicol will join a live fireside chat on September 17, 2026, to discuss recent advances in their G®CELLS graphene battery technology, including impressive long-life cycling data showing 489 ch...
Oracle Corporation reported a record Q1 revenue of $19.3 billion, a 30% increase year-over-year, driven by growth in Cloud Infrastructure and customer prepayments. Despite improved cash flow from prepayments, the company faces risks from high custome...
Shiba Inu (SHIB) has seen a sharp 78% decline in its seven-day moving average of mean exchange outflows, a key metric that previously indicated bullish momentum. This drop means fewer tokens are leaving exchanges, suggesting less movement away from t...
Lakefront Biotherapeutics, formerly Galapagos, rebranded and acquired Ouro Medicines' assets with Gilead, creating a new drug development platform. The company has €2.24 billion in liquidity to support clinical trials for gamgertamig, a drug targetin...
EraNova Metals has filed an independent NI 43-101 technical report confirming robust economics for its 100% owned Adanac Molybdenum Project in British Columbia. The Preliminary Economic Assessment shows a pre-tax NPV of C$1.2 billion and an IRR of 30...
